Why Arrowhead Pharmaceuticals, Inc. (ARWR) stock moved
Arrowhead Pharmaceuticals, Inc. (ARWR) shares fell 3.6% to $71.65 as of July 21, 2026, a moderate decline from the prior close of $74.30. BestStocks flagged the session as a major change for ARWR. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for ARWR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ARWR fell 3.6% to $71.65
ARWR fell 3.6% in its latest session, moving from $74.30 to $71.65.
What it means for Arrowhead Pharmaceuticals, Inc. investors
For Arrowhead Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.09% from $71.38 to $74.30 on 2026-07-17. Weighing against that: Negative session, down 3.6%; Arrowhead Pharmaceuticals, Inc. (ARWR) moved -9.05% from $84.00 to $76.40 on 2026-07-10. Wall Street's consensus price target sits at $85.83, implying +19.8% upside from $71.65. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.
ARWR price reaction
ARWR last traded at $71.65, down $2.65 (-3.57%) from the previous close of $74.30. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $71.38 and $86.97, and it currently sits about 2% of the way up that band.
Bullish and bearish analyst opinions on Arrowhead Pharmaceuticals, Inc. (ARWR)
The consensus analyst price target on Arrowhead Pharmaceuticals, Inc. (ARWR) is $85.83, 19.8% above the recent $71.65. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ARWR line up.
The bullish case
- Wall Street's consensus price target of $85.83 implies +19.8% upside from $71.65.
- The Street's most bullish target is $100.00 (+39.6%).
- Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.09% from $71.38 to $74.30 on 2026-07-17.
The bearish case
- The most bearish analyst target is $46.00 (-35.8%).
- Negative session, down 3.6%.
- Arrowhead Pharmaceuticals, Inc. (ARWR) moved -9.05% from $84.00 to $76.40 on 2026-07-10.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ARWR
Frequently asked questions about ARWR
Why did Arrowhead Pharmaceuticals, Inc. (ARWR) stock move?
ARWR fell 3.6% to $71.65. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ARWR stock fall?
ARWR lost 3.57% ($2.65) versus the prior close of $74.30, last trading at $71.65 on 1.1× average volume.
When is Arrowhead Pharmaceuticals, Inc.'s next earnings date?
ARWR's next earnings report is estimated for 2026-08-06 — about 16 days away.
What is the analyst price target for ARWR?
The consensus analyst price target for ARWR is $85.83, about 19.8% above the current $71.65. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks ARWR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ARWR-specific materiality thresholds, triggering an evidence check. It draws on 11 tracked change events for ARWR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.